Sartorius Stedim Biotech: Information on Document Availability
July 21 2017 - 2:21AM
Business Wire
Regulatory News:
The Investor Relations news on the first half 2017 results of
Sartorius Stedim Biotech Group (BOURSE: DIM) is now available
at
http://www.sartorius-france.fr/en/company/investor-relations/sartorius-stedim-biotech-sa/
It contains the following information:
- Business development for the period of January to June 2017 as
well as the 2017 full year forecast for the Sartorius Stedim
Biotech Group
- Consolidated financial statements for the period ended June
30, 2017
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of
products and services that enable the biopharmaceutical industry to
develop and manufacture drugs safely and efficiently. As a total
solutions provider, Sartorius Stedim Biotech offers a portfolio
covering nearly all steps of biopharmaceutical manufacture. The
company focuses on single-use technologies and value-added services
to meet the rapidly changing technology requirements of the
industry it serves. Headquartered in Aubagne, France, Sartorius
Stedim Biotech is quoted on the Eurolist of Euronext Paris. With
its own manufacturing and R&D sites in Europe, North America
and Asia and an international network of sales companies, Sartorius
Stedim Biotech has a global reach. In 2016, the company employed
approx. 4,700 people, and earned sales revenue of 1,052 million
euros.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170720006452/en/
Sartorius Stedim Biotech S.A.Petra Kirchhoff | Vice President of
Corporate Communications and IR+49
(0)551.308.1686petra.kirchhoff@sartorius.com
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Oct 2024 to Nov 2024
WisdomTree International... (AMEX:DIM)
Historical Stock Chart
From Nov 2023 to Nov 2024
